Simulations Plus, Inc. (AMEX: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported preliminary financial results for the third fiscal quarter of its 2006 fiscal year ended May 31, 2006, and announced that the company’s CEO will be presenting at the Wall Street Reporter Small-Cap Discovery Conference in New York on Wednesday, June 21, 2006.
Ms. Momoko Beran, chief financial officer of Simulations Plus, stated: “Consolidated revenues for the third quarter were $1,789,000, an increase of 25.6% from $1,424,000 in the third quarter of fiscal year 2005. This is not only a new record for third quarter revenues, but is a record for all quarters when multi-year licenses are recognized ratably (year-by-year rather than up front). Revenues from pharmaceutical software and services were $1,097,000, an increase of 65.7% from $662,000 in the third quarter of fiscal year 2005. Revenues for our Words+ subsidiary decreased 9.2% to $692,000 from $762,000 in the third quarter of fiscal year 2005. Final earnings will not be known until we complete the auditors’ review and tax calculations, but we estimate at this time that earnings for the quarter should be in the range of $0.07-0.11 per share.”
“For the first nine months, revenues were $4,089,000, an increase of 16.1% over $3,523,000 for the first nine months of fiscal year 2005. Sales of pharmaceutical software licenses and services in the first nine months were $2,179,000, an increase of 36.5% over $1,596,000 in the first nine months of fiscal year 2005. Words+ sales were $1,910,000, a decrease of 0.8% from $1,926,000 in the previous fiscal year. Again, earnings will not be known for a few more weeks, but we estimate that earnings for the first nine months will be in the range of $0.08-0.12 per share. Cash flow is good and our cash and equivalents at the end of the third quarter exceeded $1 million. The Company remains debt-free.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus, noted: “Although it is no longer our practice to provide preliminary results, our decision to do so at this time was due to our participation in Wall Street Reporter’s Small-Cap Discovery Conference and, clearly, we’re very pleased with these preliminary results. In my travels I have been receiving very positive feedback from both large and small customers, with a number of them indicating they plan to increase their number of software licenses and obtain training for additional scientists. The pharmaceutical industry seems to be adopting simulation and modeling software at an accelerating rate. The recent move by Novartis in setting up a separate Simulation and Modeling Department headed by a vice president demonstrates the growing recognition of higher level industry management of the importance of these technologies.”